

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **LOAN FACILITY WITH CHINA MINSHENG BANK HONG KONG BRANCH- ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES**

The Company, as borrower, entered into the Loan Agreement with China Minsheng Bank Hong Kong Branch for a term loan facility equal to equivalent of HK\$300,000,000.

The Loan Agreement imposes, among other matters, specific performance obligations on the controlling shareholders of the Company.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) announces that the Company, as borrower, entered into a loan agreement (the “Loan Agreement”) dated 19 May 2022 with China Minsheng Banking Corp., Ltd Hong Kong Branch for a term loan facility equal to equivalent of HK\$300,000,000. The term loan facility shall be available for drawdown within 3 months from the date of the Loan Agreement. The term loans under the facility shall be repaid by instalments as 20%, 20%, 20% and 40% of all loans outstanding on the last date of available period in the 18, 24, 30 and 36 months respectively from the date of first drawdown.

The Loan Agreement imposes, among other matters, Mr. Tsoi Hoi Shan, Ms. Choy Siu Chit, Ms. Ning Kwai Chun and their family trusts (individually or collectively, directly or indirectly) (i) remain the single largest shareholder of the Company; (ii) hold beneficially at least 40% of the issued share capital of the Company; and (iii) have management control over the Company or the group.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

On behalf of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 15 June 2022

*As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.*